Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities is a research paper published in Pharmacology & Therapeutics (2020). On theSindex it has a DataRank of 0.612. It has been cited 58 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.612
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Intramural NIH HHS
Grant: Z01 ES025034
National Institutes of Health
Grant: 1Z01ES025034-14
Characterization And Functional Significance Of P450 Arachidonate Epoxygenases
National Institute of Environmental Health Sciences
Tongji Hospital
National Natural Science Foundation of China
FWCI
6.91
Citation Percentile
1.0%
Influential Citations
6
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike
Additional file 1 of Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike
Additional file 2 of Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike
Additional file 2 of Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike